Cook SJ - Search Results

1

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.

Little AS, Smith PD, Cook SJ. Little AS, et al. Among authors: cook sj. Oncogene. 2013 Mar 7;32(10):1207-15. doi: 10.1038/onc.2012.160. Epub 2012 May 7. Oncogene. 2013. PMID: 22562245 Review.

2

Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells.

Balmanno K, Cook SJ. Balmanno K, et al. Among authors: cook sj. Oncogene. 1999 May 20;18(20):3085-97. doi: 10.1038/sj.onc.1202647. Oncogene. 1999. PMID: 10340380

3

Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Squires MS, Nixon PM, Cook SJ. Squires MS, et al. Among authors: cook sj. Biochem J. 2002 Sep 1;366(Pt 2):673-80. doi: 10.1042/BJ20020372. Biochem J. 2002. PMID: 12069688 Free PMC article.

4

Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.

Garner AP, Weston CR, Todd DE, Balmanno K, Cook SJ. Garner AP, et al. Among authors: cook sj. Oncogene. 2002 Nov 21;21(53):8089-104. doi: 10.1038/sj.onc.1206000. Oncogene. 2002. PMID: 12444545

5

Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways.

Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ. Weston CR, et al. Among authors: cook sj. Oncogene. 2003 Mar 6;22(9):1281-93. doi: 10.1038/sj.onc.1206261. Oncogene. 2003. PMID: 12618753

6

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Ley R, et al. Among authors: cook sj. J Biol Chem. 2003 May 23;278(21):18811-6. doi: 10.1074/jbc.M301010200. Epub 2003 Mar 19. J Biol Chem. 2003. PMID: 12646560 Free article.

7

Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3'-kinase (PI3K) pathway is inhibited.

Molton SA, Todd DE, Cook SJ. Molton SA, et al. Among authors: cook sj. Oncogene. 2003 Jul 24;22(30):4690-701. doi: 10.1038/sj.onc.1206692. Oncogene. 2003. PMID: 12879014

8

ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest.

Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L, Cook SJ. Todd DE, et al. Among authors: cook sj. Oncogene. 2004 Apr 22;23(19):3284-95. doi: 10.1038/sj.onc.1207467. Oncogene. 2004. PMID: 14981547

9

The conditional kinase DeltaMEKK1:ER* selectively activates the JNK pathway and protects against serum withdrawal-induced cell death.

Molton SA, Weston C, Balmanno K, Newson C, Todd DE, Garner AP, Cook SJ. Molton SA, et al. Among authors: cook sj. Cell Signal. 2005 Nov;17(11):1412-22. doi: 10.1016/j.cellsig.2005.02.006. Cell Signal. 2005. PMID: 15893455

10

The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1.

Chalmers CJ, Gilley R, March HN, Balmanno K, Cook SJ. Chalmers CJ, et al. Among authors: cook sj. Cell Signal. 2007 Apr;19(4):695-704. doi: 10.1016/j.cellsig.2006.09.001. Epub 2006 Sep 15. Cell Signal. 2007. PMID: 17052890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters